Navigation Links
Clinical trial tests rice bran to prevent cancer
Date:12/5/2012

A recent University of Colorado Cancer Center review in the journal Advances in Nutrition shows that rice bran offers promising cancer prevention properties. Meanwhile, an ongoing clinical trial is testing the effectiveness of rice bran in preventing the recurrence of colon cancer.

"While I have been trained as a molecular toxicologist, I am excited about the opportunities to deliver bioactive, cancer fighting compounds with food, and this has led to my focus now primarily on the multiple drug-like characteristics of rice bran," says Elizabeth P. Ryan, PhD, CU Cancer Center investigator, assistant professor in the Department of Environmental and Radiological Health Sciences at the CSU Animal Cancer Center, and the review's senior author. "There's a delicate balance of bioactive components in rice bran that together show anti-cancer activity including the ability to inhibit cell proliferation, alter cell cycle progression and initiate the programmed cell death known as apoptosis in malignant cells," Ryan says.

Ryan and colleagues show that bioactive rice bran derived small molecules include, but are not limited to polyphenolics, ferulic acid, tricin, β-sitosterol, γ-oryzanol, tocotrienols/tocopherols, and phytic acid.

"We're working now to tease apart the ratios of these active molecules required for bioactivity and mechanisms. Previous attempts to isolate one or another compound have been largely unsuccessful and so it looks now as if rather than any one compound giving rice bran its chemopreventive powers, it's the synergistic activity of multiple components in the whole food that should be studied."

Work with cancer cell lines and animal models shows that the bioactive components of rice bran act not only within cancer cells but around the cells to create conditions in the surrounding tissues that promote the function of healthy cells while inhibiting the function of cancer cells. This tissue microenvironment activity includes mediating chronic inflammation that provides a ripe landscape for cancer. Ryan and colleagues including Tiffany Weir, PhD, and Rajesh Agarwal, PhD, are collaborating to evaluate how rice bran may also help to promote an anti-cancer immune response and modulate gut microbiota metabolism for protection against cancer.

"There are well over 100,000 varieties of rice in the world, many with their own unique mix of bioactive components and so one major challenge is to discover the optimal composition for chemoprevention. Another challenge is ensuring that people consistently receive the required daily intake amount or 'dose' needed to demonstrate these chemo-protective effects. That said, rice is an accessible, low-cost food in most places of the world, and so work with rice bran as a dietary chemopreventive agent has the potential to impact a significant portion of the world's population," Ryan says.

Ryan has taken the next step in the evolution of rice bran from diet to prescription, in the form of an ongoing clinical trial testing its chemopreventive effectiveness in a population of colon cancer survivors.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
2. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
3. New clinical trial explores novel noninvasive colon cancer screening test
4. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
5. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
6. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
7. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
8. AAO-HNS releases updated Clinical Indicators
9. Sequencing works in clinical setting to help -- finally -- get a diagnosis
10. VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests
11. Clinical trials for Alzheimers disease preventative drug to begin early 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate Growth ... analysis of the digital and computed radiography markets in ... , and Indonesia (TIM). It ... market size, as well as regional market drivers and ... discusses market penetration and market attractiveness, both for digital ...
(Date:2/1/2016)... 2016  Wocket® smart wallet ( www.wocketwallet.com ) announces the launch of ... Fatone . Las Vegas , where Joey appeared ... Las Vegas , where Joey appeared at the Wocket ... video ad was filmed at the Consumer Electronics Show (CES2016) in ... to meet and greet fans. --> ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... 11, 2016   BioInformant announces the February ... Research Products, Opportunities, Tools, and Technologies – Market Size, ... The first and ... cell industry, BioInformant has more than a decade of ... market, by stem cell type. This powerful 175 page ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global ... treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols and ... from around the world. , The new GSCG clinic is headed by ...
(Date:2/10/2016)... -- The Maryland House of Delegates and House Speaker ... Maryland School of Medicine Dean E. Albert Reece ... System President and CEO Robert Chrencik , MBA, ... given to the public by the leader of the ... and Mr. Chrencik for their contributions to our statewide ...
(Date:2/10/2016)... New York (PRWEB) , ... ... ... Inc. (NASDAQ: REGN) today announced that it has joined the Human Vaccines ... immunotherapies for infectious diseases and cancer. , The Human Vaccines Project ...
Breaking Biology Technology: